UK Legal Status & Schedules Matrix
Statutory classification matrix evaluating the legal status of synthetic research peptides in the United Kingdom under the Human Medicines Regulations 2012 (SI 2012/1916), the Misuse of Drugs Act 1971, the Psychoactive Substances Act 2016, and the World Anti-Doping Code (WADA).
In the United Kingdom, peptides that have not received an MHRA Marketing Authorisation are strictly classified as unlicensed chemical substances. It is lawful for commercial entities to supply and for laboratory researchers to purchase these reagents exclusively for in vitro academic, diagnostic, or assay calibration procedures. Supplying, dispensing, or advertising these substances for human administration or therapeutic consumption is a serious statutory offence.
12-Compound UK Statutory Classification Matrix
Cross-referenced against UK Primary Legislation & WADA 2026 Prohibited List
| Compound & CAS | Human Medicines Regs 2012 | Misuse of Drugs Act 1971 | Psychoactive Sub. 2016 | WADA Anti-Doping Status | UK Laboratory Permissibility |
|---|---|---|---|---|---|
| BPC-157 (Body Protection Compound) CAS 137525-51-0 | Unlicensed Medicinal Substance | Non-Controlled Substance | Exempt (Non-Psychoactive Target) | Prohibited: S0 (Unapproved Substances) | Permitted: Strictly In Vitro Academic Research |
| TB-500 (Thymosin Beta-4 Derivative) CAS 77591-33-4 | Unlicensed Medicinal Substance | Non-Controlled Substance | Exempt (Non-Psychoactive Target) | Prohibited: S2 (Peptide Hormones) | Permitted: Strictly In Vitro Academic Research |
| Semax (Heptapeptide ACTH 4-10 Analogue) CAS 80714-61-0 | Unlicensed Medicinal Substance | Non-Controlled Substance | Exempt (Non-Psychoactive Target) | Prohibited: S0 (Unapproved Substances) | Permitted: Strictly In Vitro Academic Research |
| Selank (Tuftsin Analogue) CAS 129954-34-3 | Unlicensed Medicinal Substance | Non-Controlled Substance | Exempt (Non-Psychoactive Target) | Prohibited: S0 (Unapproved Substances) | Permitted: Strictly In Vitro Academic Research |
| CJC-1295 (with DAC) CAS 863288-34-0 | Unlicensed Medicinal Substance | Non-Controlled Substance | Exempt (Non-Psychoactive Target) | Prohibited: S2 (Peptide Hormones) | Permitted: Strictly In Vitro Academic Research |
| Ipamorelin CAS 170851-70-4 | Unlicensed Medicinal Substance | Non-Controlled Substance | Exempt (Non-Psychoactive Target) | Prohibited: S2 (Peptide Hormones) | Permitted: Strictly In Vitro Academic Research |
| GHK-Cu (Copper Tripeptide-1) CAS 49557-75-7 | Unlicensed Medicinal Substance | Non-Controlled Substance | Exempt (Non-Psychoactive Target) | Non-Prohibited (Topical Reagent) | Permitted: Strictly In Vitro Academic Research |
| Epithalon (Epithalamin Synthetic Tetrapeptide) CAS 307297-39-8 | Unlicensed Medicinal Substance | Non-Controlled Substance | Exempt (Non-Psychoactive Target) | Prohibited: S0 (Unapproved Substances) | Permitted: Strictly In Vitro Academic Research |
| MOTS-c (Mitochondrial-Derived Peptide) CAS 1627580-64-6 | Unlicensed Medicinal Substance | Non-Controlled Substance | Exempt (Non-Psychoactive Target) | Prohibited: S2 (Peptide Hormones) | Permitted: Strictly In Vitro Academic Research |
| Tirzepatide CAS 2023788-19-2 | Prescription Only Medicine (POM) | Non-Controlled Substance | Exempt (Non-Psychoactive Target) | Non-Prohibited (Topical Reagent) | Permitted: Analytical Laboratory Controls Only |
| Semaglutide CAS 910463-68-2 | Prescription Only Medicine (POM) | Non-Controlled Substance | Exempt (Non-Psychoactive Target) | Non-Prohibited (Topical Reagent) | Permitted: Analytical Laboratory Controls Only |
| AOD-9604 (C-Terminal Lipolytic Fragment 177-191) CAS 221231-10-3 | Unlicensed Medicinal Substance | Non-Controlled Substance | Exempt (Non-Psychoactive Target) | Prohibited: S2 (Peptide Hormones) | Permitted: Strictly In Vitro Academic Research |
Regulation 46 vs Regulation 167 & MHRA Guidance Note 8
The legal demarcation governing research chemical distribution in the United Kingdom rests upon clear statutory boundaries established under the Human Medicines Regulations 2012 (SI 2012/1916) and European Case Law (C-27/08 and C-140/07).
Regulation 46 (Prohibition): Mandates that no medicinal product may be placed on the UK market, distributed, or supplied without a valid Marketing Authorisation granted by the Licensing Authority (MHRA). Violation of Regulation 46 is a strict-liability criminal offense carrying statutory penalties including seizure and prosecution under Section 279.
Regulation 167 (Research & Specials Exemption): Creates an explicit statutory exemption for the supply of unlicensed substances for scientific investigations, in-vitro assays, and laboratory control calibrations. Chemical reagents supplied with clear labeling ("For In Vitro Laboratory Research Only"), devoid of dosing guidelines or therapeutic marketing, fall squarely outside the remit of medicinal marketing authorizations.
Under Section 2 of SI 2012/1916 and MHRA Guidance Note 8 ("A guide to what is a medicinal product"), a substance is legally classified as a medicine if it satisfies either of two distinct legal limbs:
A product is a medicine if presented as possessing properties for treating, preventing, or diagnosing disease. Advertising human health benefits, patient testimonials, or offering dosage advice legally categorizes the product under Limb 1, resulting in immediate MHRA enforcement notices.
A product is a medicine if administered to human beings with a view to restoring, correcting, or modifying physiological functions. Because synthetic peptides possess cellular bioactivity, vendors avoid Limb 2 exclusively by strictly supplying them for non-human, in-vitro experimental systems.
Rule 12.11 of the UK Code of Non-broadcast Advertising (CAP Code) strictly prohibits advertising prescription-only medicines or unlicensed medicinal products to the general public across search, social media, and digital banners.
Scientific registries must present objective, chemical, and literature-indexed information without marketing hype, discount promotion codes, before-and-after imagery, or lifestyle enhancement claims.
Breaches of CAP Code 12.11 trigger referral to the MHRA Borderline Section, resulting in mandatory website takedowns, payment gateway revocations, and Trading Standards prosecutions under consumer protection laws.
None of the 12 listed synthetic peptides are scheduled as controlled drugs under Schedules 1–5 of the Misuse of Drugs Regulations 2001. Unlike anabolic steroids (Class C Schedule 4 Part II), non-steroidal peptide reagents do not fall under controlled substance licensing mandates.
Unlicensed medicinal substances may be lawfully transferred for laboratory research. However, selling or advertising them with medical claims or dosage guidance constitutes a breach of Regulation 46 and Regulation 279, subject to MHRA statutory enforcement and prosecution.
UK Border Force permits importation of legitimate research chemical reagents under Commodity Code HS 2937.19.0000. Consignments must include commercial invoices declaring in vitro research use and matching Certificates of Analysis.